Viewing Study NCT04250350


Ignite Creation Date: 2025-12-24 @ 4:52 PM
Ignite Modification Date: 2026-01-01 @ 11:47 PM
Study NCT ID: NCT04250350
Status: COMPLETED
Last Update Posted: 2023-02-24
First Post: 2020-01-30
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Sponsor: Eli Lilly and Company
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Atopic Dermatitis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Eczema View
None Dermatitis View
None Dermatitis, Atopic View
None Skin Diseases View